A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
12
Oral tablet
Oral tablet
CenExel ACT- Anaheim Clinical Trials /ID# 282482
Anaheim, California, United States
Maximum Observed Plasma Concentration (Cmax) of Nacresertib
Cmax of Nacresertib
Time frame: Up to 9 Days
Time to Cmax (Tmax) of Nacresertib
Tmax of Nacresertib
Time frame: Up to 9 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Nacresertib
AUCt of Nacresertib
Time frame: Up to 9 Days
AUC From Time 0 to the Time Infinity (AUCinf) of Nacresertib
AUCinf of Nacresertib
Time frame: Up to 9 Days
Terminal Phase Elimination Rate Constant (Beta) of Nacresertib
Beta of Nacresertib
Time frame: Up to 9 Days
Terminal Phase Elimination Half-Life (t1/2) of Nacresertib
t1/2 of Nacresertib
Time frame: Up to 9 Days
Number of Participants Experiencing Adverse Events (AEs)
Any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Time frame: Up to 42 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.